ArticleJournal of diabetes research2026
Caffeoylquinic Acids From Lonicera japonica Thunb. as Hypoglycemic Agents: Network Pharmacology and Pharmacological Validation.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Caffeoylquinic Acids From Lonicera japonica Thunb. as Hypoglycemic Agents: Network Pharmacology and Pharmacological Validation.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The global increase in Type 2 diabetes (T2D) presents a serious public health challenge. Lonicera japonica Thunb., a traditional medicinal and edible plant, is a rich source of caffeoylquinic acids (CQAs), which are naturally occurring polyphenols that have drawn considerable research interest due to their diverse biological activities, particularly their potential in the management of T2D. In this study, six CQAs were isolated from the flower buds of L. japonica using preparative HPLC, with a total yield of 0.0555 mg/g. These compounds were identified as 3-CQA, 4-CQA, 5-CQA, 3,4-DCQA, 3,5-DCQA, and 4,5-DCQA, and their structures were characterized by LC-DAD-ESI-QTOF-MS and NMR. Hypoglycemic activity was then assessed using α-glucosidase/α-amylase inhibition, glucose uptake, and hepatic glucose production assays. Network pharmacology predicted potential targets and pathways, which were then validated by dual-luciferase reporter and Western blot analyses. Results showed that CQAs selectively inhibited α-glucosidase (not α-amylase), enhanced glucose uptake, and suppressed hepatic glucose production. Among them, the di-CQAs, particularly 4,5-DCQA and 3,5-DCQA, were the most potent α-glucosidase inhibitors, with IC₅₀ values of 5.49 and 7.96 mM, respectively. Network analysis identified AKT1, PEPCK, and INSR as core targets, and PI3K/AKT, insulin, and FoxO signaling pathways as key pathways. Mechanistically, 3,5-DCQA suppressed gluconeogenesis by inhibiting PEPCK (at both promoter activity and protein levels) and downregulating CREB. It also enhanced insulin signaling via upregulation of INSR, IRS-1, and p-AKT. In conclusion, our study demonstrates that 3,5-DCQA, a key bioactive constituent of L. japonica, exerts multitarget hypoglycemic effects by coordinately regulating gluconeogenesis and insulin signaling. These findings not only provide a direct pharmacological basis for the antidiabetic potential of CQA-rich herbs but also highlight 3,5-DCQA as a promising candidate for developing novel therapeutics or adjuncts for T2D management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.